Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02291913
Title Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.